379 |
Next Generation of DES |
Alexandre Abizaid |
Sep. 20. 07 |
378 |
Two-Year Follow Up of a First-in-Man Registry with a Bioabsorbable Polymer Based Sirolimus-Eluting Stent (Medistra Excel Drug-Eluting Stent Trial - MEDISTRA Study) |
Teguh Santoso |
Sep. 20. 07 |
377 |
Triple Antiplatelet Therapy After Drug-Eluting Stenting in Patients with High Risk of Restenosis |
Seong-Wook Park |
Sep. 14. 07 |
376 |
Taking the Evidence-Based Approach to ACS: Examination of New Antithrombin Trial Data |
Gregg W. Stone |
Sep. 14. 07 |
375 |
Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High Risk PCI |
Charles A. Simonton |
Sep. 14. 07 |
374 |
Bivalirudin on Trial: Rationale and Status of ISAR-REACT 3 and 4 |
Adnan Kastrati |
Sep. 14. 07 |
373 |
Role of Cardiac CT in PCI and Assessment of Coronary Stents |
John Hoe |
Sep. 14. 07 |
372 |
Coronary CT Angiography: Merits, Applications, Limitations, Problems |
Stephan Achenbach |
Sep. 14. 07 |
371 |
How Can We Optimize Good Result in the Long Coronary Lesion ? |
Seung-Jung Park |
Sep. 07. 07 |
370 |
Chronic Total Occlusions |
David E. Kandzari |
Sep. 07. 07 |